液体活检技术在肝癌诊治中的现状和发展  

The Current Status and Development of Liquid Biopsy Technology in the Diagnosis and Treatment of Liver Cancer

作　　者：李林翰 张大志[1] 

机构地区：[1]重庆医科大学附属第二医院传染病科,重庆

出　　处：《临床医学进展》2024年第2期3794-3799,共6页Advances in Clinical Medicine

摘　　要：肝癌多是在慢性肝病基础上产生的一种肿瘤。由于其早期诊断率低,多数患者初诊时已经处于中晚期。随着基因组学技术的发展,液体活检在肝癌中的应用已被研究得较多。本文主要介绍了循环游离DNA (cfDNA)、循环肿瘤细胞(CTCs)、外泌体在肝癌的诊断、预后评价、疗效监测几个方面的应用。Liver cancer typically arises as a tumor developed from chronic liver disease. The early diagnosis rate for liver cancer is notably low, resulting in the majority of patients being diagnosed at an al-ready advanced stage. The advancements in genomic technology have led to significant research on the utility of liquid biopsy in liver cancer. This article primarily aims to explore and discuss the ap-plications of circulating free DNA (cfDNA), circulating tumor cells (CTCs), and exosomes for diagnos-tic purposes, prognosis evaluation, and treatment monitoring of liver cancer.

关 键 词：肝癌 液体活检 早期诊断 预后 

分 类 号：R73[医药卫生—肿瘤]